Relugolix + Enzalutamide Study in High-Risk Prostate Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer — Stella

Home/Androgen Deprivation Therapy/

View on ClinicalTrials.gov

Recruiting

Back to Androgen Deprivation Therapy trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Stephenson Cancer Center at OU Health, University of Oklahoma Health Sciences Center (SCC-OUHSC), Oklahoma City, Oklahoma

Key details

Phase

Early testing

Sponsor

University of Oklahoma

Collaborators

Pfizer, Astellas Pharma Inc

Enrollment target

~46 participants

Started

December 2024

Primary completion

January 2029

Age range

18 Years and older

Sex

Male only

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.